|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400090800 |
|
最近更新日期: Date of Last Refreshed on: |
2024-10-14 08:57:02 |
|
注册时间: Date of Registration: |
2024-10-14 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
比较丙泊酚、瑞马唑仑与依托咪酯对老年患者麻醉诱导后低血压的影响:一项随机对照研究 |
|
Public title: |
Comparison of propofol, remimazolam and etomidate on hypotension after anesthesia induction in elderly patients: a randomized controlled trial |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
比较丙泊酚、瑞马唑仑与依托咪酯对老年患者麻醉诱导后低血压的影响:一项随机对照研究 |
|
Scientific title: |
Comparison of propofol, remimazolam and etomidate on hypotension after anesthesia induction in elderly patients: a randomized controlled trial |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
金晓菲 |
研究负责人: |
彭科 |
|
Applicant: |
Jin Xiaofei |
Study leader: |
Peng Ke |
|
申请注册联系人电话: Applicant telephone: |
+86 185 5058 5995 |
研究负责人电话: Study leader's telephone: |
+86 159 6215 5989 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
jxf185@suda.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
pengke0422@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
江苏省苏州市十梓街188号 |
研究负责人通讯地址: |
江苏省苏州市十梓街188号 |
|
Applicant address: |
188 Shizi Street, Suzhou, Jiangsu, China |
Study leader's address: |
188 Shizi Street, Suzhou, Jiangsu, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
苏州大学附属第一医院 |
||
|
Applicant's institution: |
The First Affiliated Hospital of Soochow University |
||
|
研究负责人所在单位: |
苏州大学附属第一医院 |
||
|
Affiliation of the Leader: |
The First Affiliated Hospital of Soochow University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
(2024)伦审批第380号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
苏州大学附属第一医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of the First Affiliated Hospital of Soochow University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-09-10 00:00:00 |
||
|
伦理委员会联系人: |
吴霜杰 |
||
|
Contact Name of the ethic committee: |
Wu Shuangjie |
||
|
伦理委员会联系地址: |
中国江苏省苏州市平海路899号 |
||
|
Contact Address of the ethic committee: |
899 Pinghai Road, Suzhou, Jiangsu, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 512 6797 2743 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
苏州大学附属第一医院麻醉科 |
||||||||||||||||||||||
|
Primary sponsor: |
Department of Anesthesiology, First Affiliated Hospital of Soochow University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
江苏省苏州市十梓街188号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
188 Shizi Street, Suzhou, Jiangsu, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
机构经费 |
||||||||||||||||||||||
|
Source(s) of funding: |
Institutional funding |
||||||||||||||||||||||
|
Target disease: |
Hypotension after induction of anesthesia |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
通过比较静脉使用丙泊酚、瑞马唑仑、依托咪酯用于老年患者麻醉诱导,寻找适用于老年患者的静脉麻醉诱导药物,维持麻醉诱导期循环稳定,降低低血压发生率,减少并发症发生,保障老年患者麻醉安全。 |
||||||||||||||||||||||
|
Objectives of Study: |
By comparing the intravenous use of propofol, remimazolam, and etomidate for anesthesia induction in elderly patients, we seek intravenous anesthesia induction drugs suitable for elderly patients, maintain circulatory stability during anesthesia induction, reduce the incidence of hypotension, reduce the occurrence of complications, and ensure the safety of anesthesia in elderly patients. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
年龄≥80岁,ASA I-III级;在静脉药物麻醉诱导气管插管下行择期非心脏手术的患者;清楚了解试验过程并自愿参加本研究,签署知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
Patients aged ≥80 years, ASA physical status I-III; patients undergoing elective non-cardiac surgery under endotracheal intubation after intravenous anesthesia induction; patients who clearly understand the trial process and voluntarily participate in this study with signed informed consent. |
||||||||||||||||||||||
|
排除标准: |
BMI≥35 kg/m^2;对研究中药物过敏;严重心肺疾病、严重肝病、需要透析的肾病;麻醉前收缩压≥200mmHg和/或舒张压≥120mmHg;使用抗精神病药物、抗抑郁药物、安定或其他镇静药物;睡眠呼吸暂停或预计困难气道。 |
||||||||||||||||||||||
|
Exclusion criteria: |
BMI ≥ 35 kg/m^2; allergy to the drugs in the study; severe cardiopulmonary disease, severe liver disease, kidney disease requiring dialysis; systolic blood pressure ≥ 200 mmHg and/or diastolic blood pressure ≥ 120 mmHg before anesthesia; use of antipsychotics, antidepressants, tranquilizers or other sedatives; sleep apnea or expected difficult airway. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-10-15 00:00:00至 To 2025-10-15 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2024-10-15 00:00:00 至 To 2025-10-15 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
一名不参与后续研究的助理人员,使用在线随机化工具,以1:1:1的比例生成随机化。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
A research personnel who is not involved in the subsequent study will generate the random sequence (1:1:1) using the online randomisation tool. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
受试者盲,研究者盲,评估者盲 |
|
Blinding: |
Subjects, investigators, and evaluators are all blinded to the group allocation. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
公开发表的学术论文中公布 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Published in a publicly published academic paper |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
纸质材料及电子材料保存在苏州大学附属第一医院 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
The paper materials and electronic materials are kept in The First Affiliated Hospital of Soochow University |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |